Dec 11, 2019 · We thank the patients who participated in this trial and their families, as well as the investigators and staff at all HER2CLIMB clinical sites; the members of the independent data …

Aug 14, 2023 · A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)

Current primary analysis of phase III HER2CLIMB-02 trial evaluated efficacy and safety of tucatinib + T-DM1 in patients with previously treated HER2-positive LA/MBC8

Jul 7, 2025 · Abstract Tucatinib has significantly advanced the treatment of HER2-positive metastatic breast cancer. When used in combination with trastuzumab and capecitabine, it …

May 31, 2023 · HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.. If …

May 2, 2024 · This is the first report of HER2CLIMB-02 (NCT03975647), a randomized, double-blind, placebo-controlled phase 3 study assessing the efficacy and safety of tucatinib …

Learn more about the HER2CLIMB clinical trial including the trial design, endpoints and more. Read full indication and important safety information.

Trial design HER2CLIMB-04 (NCT04539938) is a single-arm, open-label phase 2 trial evaluating the efficacy and safety of TUC + T-DXd in pts with HER2+ unresectable, locally advanced or …

Nov 1, 2023 · The regulatory recommendations are based on data from the HER2CLIMB trial, which randomized patients with metastatic BC to receive trastuzumab and capecitabine with …

Feb 1, 2023 · Design, setting, and participants: HER2CLIMB is an international, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating tucatinib in combination …